It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... View Research predicted that the value of pharmaceutical manufacturing worldwide was $516.48 billion in 2022.

Glaxo Wellcome agreed to pay the University royalties on the worldwide sale of Ziagen, an AIDS-inhibiting drug, University President Mark Yudof announced Tuesday. About two-thirds of the royalty ...

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn. A panel of leaders at the PMCPA, pharma’s ...

Canada has announced a deal to secure 500K doses of GSK’s (NYSE:GSK) avian influenza vaccine for humans as the country steps up efforts to protect at-risk individuals and bolster its federal ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...